Tongxin Micro Making a Splash at TRUSTECH, and Unveiling the World’s First eSIM Solution Tailored for Smart POS Systems
29.11.2023 20:00:00 EET | Business Wire | Press release
November 28th marks the grand opening of TRUSTECH 2023 in Paris, France. Tongxin Micro, an industry-leading semiconductor solution provider, makes an impressive debut, showcasing its technological advancements in identity recognition, telecommunications, and financial payments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129462718/en/
(Photo: Business Wire)
In the realm of identity recognition, Tongxin Micro brings its document chip solutions in compliance with international ICAO standards that boast the highest security levels globally, catering to such applications as seafarer’s passport and official passport. In telecommunications, a full array of products and terminal applications are displayed, including standard SIM, SWP-SIM, digital car keys based on SWP-SIM, and eSIM wearable devices. In the payment sector, Tongxin Micro’s innovative payment technologies draw significant attention, ranging from chip applications in payment IC cards, display cards, fingerprint cards, and e-CNY hardware wallets, to MCU chips for safety-critical products, such as POS, online identity authentication, IoT SE, and biometric identification.
In addition, John Zou, EVP of Tongxin Micro, shares the world’s first eSIM solution tailored for smart POS systems at the Innovation Stage. He expresses that, "Currently, smart POS systems require to switch among multiple SIM cards to connect to different networks, which is a tedious and unsafe process, and thus compromising business service efficiency and user experience. Our solution, designed with the world-class security chips in an embedded manner, features high information security. It enables online activation of eSIM, allowing the switch between different carriers freely to save deployment costs. This solution comes with wafer-level personalization services, saving significant board-level space, and we can also provide customized one-stop solutions to meet the diverse needs of customers both at home and abroad.” To date, this solution has been adopted by several well-known terminal device manufacturers.
Bearing its mission of achieving more intelligent, more convenient, and more secure digital experience in mind, Tongxin Micro has deepened its footprint in the fields of automotive electronics and smart chip. The company is steadily accelerating its global expansion, with business spanning over twenty countries and regions in Asia, Europe, Americas, and Africa. Tongxin Micro looks forward to continuously creating more competitive new technologies and solutions for global customers, and jointly forging ahead for a brighter future in digital economy.
For more information: www.tsinghuaic.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231129462718/en/
Contact information
Tongxin Microelectronics Co., Ltd.
Steve Sun
sunhb01@tsinghuaic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom